Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Australia, NZ Again Drop Plan For Joint Therapeutic Product Regulator

This article was originally published in The Tan Sheet

Executive Summary

Australia and New Zealand once again ditch plans for a joint drug, nutritional product and medical device regulator, wiping away all made in three years to harmonize the two countries' regulatory frameworks.

You may also be interested in...



NZ Plans Major Regulatory Overhaul, New Independent Agency

The New Zealand health ministry has launched a consultation on a wide-ranging overhaul of the therapeutic product regulatory system. The new scheme, which will take a few years to put into place, will fill a number of regulatory gaps, set up a new independent drugs and devices agency,  and generally bring New Zealand into line with other regulatory systems around the world.

Therapeutic Product Regulatory Reforms Considered Down Under

Australia's Therapeutic Goods Association plans to implement a number of regulations to update and streamline the existing framework for over-the-counter and prescription drugs as well as medical devices

Could Alcon's CyPass Trouble Be Boon For Glaukos – Or Bust For MIGS?

Minimally invasive glaucoma surgery specialist Glaukos saw its stock leap 40% in the wake of a worldwide recall by much bigger rival Alcon of its CyPass microstent.

Topics

UsernamePublicRestriction

Register

PS107329

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel